How changes in certain fats affect cancer cell behavior.
Phosphatidylserine acyl chain remodeling regulates KRAS spatial distribution and function on the plasma membrane.
['FUNDING_R01'] · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · NIH-10814769
This study is looking at how certain fats in cancer cells can change the way cancer grows, especially in cancers with a KRAS gene mutation, and it hopes to find new ways to treat these types of cancer by changing those fats.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON (nih funded) |
| Locations | 1 site (HOUSTON, UNITED STATES) |
| Trial ID | NIH-10814769 on ClinicalTrials.gov |
What this research studies
This research investigates the role of specific fat molecules, called phosphatidylserines, in the behavior of cancer cells, particularly those with mutations in the KRAS gene. By altering the types of these fats present in cancer cells, the study aims to disrupt the way KRAS proteins cluster on the cell membrane, which is crucial for their function in promoting cancer growth. The researchers will use techniques to modify these fat molecules and observe the effects on cancer cell signaling and proliferation. This approach could lead to new strategies for treating cancers that are driven by KRAS mutations.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with pancreatic, colorectal, or lung cancers that exhibit KRAS mutations.
Not a fit: Patients without KRAS mutations or those with other types of cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to innovative treatments for patients with KRAS-driven cancers, potentially improving outcomes.
How similar studies have performed: While the specific approach of modifying phosphatidylserine acyl chains is novel, there have been successful studies targeting KRAS in cancer treatment, indicating potential for this line of inquiry.
Where this research is happening
HOUSTON, UNITED STATES
- UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON — HOUSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ZHOU, YONG — UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
- Study coordinator: ZHOU, YONG
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancers, neoplasm/cancer